The Pioneer Brief

Helping Pioneer practices differentiate in their markets and communicate the value of advanced NeuroAI capabilities to patients, healthcare professionals, and referral sources. That may include patient acquisition, local marketing support, physician referrals, Pioneer clinic profiles, digital and social content, patient-facing materials, case studies, videos and interviews, practice-development tools, and Pioneer branding.

During November, we will ask you to identify your highest marketing priorities, then develop a Pioneer Marketing & Practice Growth Plan and bring it back to the community.

Areas of current interest include concussion and TBI, Parkinson’s disease, mild cognitive impairment, multiple sclerosis, vestibular migraine, dizziness and balance disorders, fall risk, neurodegenerative disease, healthy aging, and longitudinal neurological change.

We intend to begin developing a Pioneer Research Network connecting interested clinicians with our scientific team and, where appropriate, academic and research collaborators. Opportunities may include participating as a research site, helping develop protocols, proposing research questions, participating in case studies, contributing appropriately governed data, and collaborating on appropriately structured studies. The specifics of participation, data use, recognition, acknowledgments, and authorship will depend upon each project and applicable research standards and agreements.

There is significant expertise within the Pioneer community. The expanded program will include Master Classes, online training, clinical case conferences, research discussions, technology previews, roundtables, clinical working groups, leadership updates, clinician interviews, and practice spotlights. We are also exploring the creation of a Pioneer Advisory Council, together with focused working groups around research, education, technology, clinical development, and practice growth.

Our direction is to create meaningful distinctions based on education, credentialing, technology, platform access, and advanced clinical capabilities. Owning NeuroAI-enabled equipment will not by itself provide access to every capability of the platform: advanced functionality will be associated with appropriate technology, training, credentialing, competency, scope of practice, and applicable regulatory requirements. Our intention is for appropriately credentialed Pioneer clinicians to be positioned at the advanced end of this network.

Our objective is a network in which expansion creates additional opportunities for advanced clinicians. As more clinicians use NeuroAI technology, more patients can potentially be assessed; as more patients are assessed, more advanced and complex cases may be identified. We intend to explore structured referral pathways connecting appropriate cases with clinicians who have the training, credentialing, technology, and expertise to manage them.

Our strategy is focused primarily on clinical differentiation rather than broad geographic exclusivity. Spryson technology is already present in a variety of hospitals and clinical settings, making broad exclusivity impractical in many markets. Instead, we intend to differentiate Pioneer practices through credentialing, education, technology, platform capabilities, advanced programs, professional positioning, and potential referral opportunities. As we develop the network, we also intend to communicate with existing Pioneers regarding plans to add additional Pioneer practices within their established markets.

We see AI as a tool for increasing the capabilities of appropriately trained clinicians. As NeuroAI datasets grow, AI may help identify patterns, organize complex information, support analysis, and provide clinical decision-support tools. It does not eliminate the importance of clinical expertise: qualified clinicians remain responsible for clinical interpretation, patient management, and clinical decisions within their scope of practice. Increasingly sophisticated technology can make advanced clinical training and judgment even more important.

We intend to create structured opportunities for interested Pioneer clinicians to participate in appropriately designed research and clinical-development initiatives. The nature of participation, data use, research governance, attribution, acknowledgments, and authorship will depend upon the specific project, applicable agreements, individual contribution, research standards, and regulatory and ethical requirements. Additional details will be provided as individual research programs are developed.

Patient privacy and data security remain fundamental requirements of the NeuroAI platform. Patient information will be handled in accordance with applicable privacy and security requirements and governing agreements, including Business Associate Agreements where applicable. As new research, AI, data, and At-Home initiatives are introduced, we will communicate the applicable requirements and data practices associated with those programs.

The rights and obligations of Spryson and each Pioneer continue to be governed by the applicable executed agreements between the parties. Where additional terms or modifications are appropriate, those will be addressed through applicable contractual documentation. The expanded Pioneer Success Program is intended to create additional programs, education, resources, opportunities, and support around the Pioneer relationship.